Top Page
Mach7 Technologies
(Sydney:M7T)
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Mach7 Technologies Business Overview & Revenue Model
Mach7 Technologies Earnings Call Summary
Mach7 Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.79M | 33.79M | 17.24M | 30.06M | 27.08M | 19.03M |
| Gross Profit | 8.38M | 8.38M | -6.42M | 9.35M | -2.57M | -7.73M |
| EBITDA | -7.06M | -7.06M | -15.09M | 2.09M | 2.80M | -1.83M |
| Net Income | -6.20M | -6.20M | -7.97M | -1.05M | -4.17M | -9.36M |
Balance Sheet | ||||||
| Total Assets | 64.21M | 64.21M | 73.03M | 82.31M | 78.92M | 76.97M |
| Cash, Cash Equivalents and Short-Term Investments | 23.07M | 23.07M | 26.18M | 23.39M | 25.75M | 18.36M |
| Total Debt | 1.12M | 1.12M | 1.27M | 1.20M | 1.33M | 1.08M |
| Total Liabilities | 18.63M | 18.63M | 21.17M | 22.82M | 20.55M | 19.05M |
| Stockholders Equity | 45.58M | 45.58M | 51.86M | 59.48M | 58.38M | 57.91M |
Cash Flow | ||||||
| Free Cash Flow | 112.92K | 112.92K | 3.30M | -2.97M | 5.94M | 1.40M |
| Operating Cash Flow | 868.59K | 868.59K | 3.45M | -2.61M | 6.37M | 1.50M |
| Investing Cash Flow | -1.70M | -1.70M | -391.31K | -361.01K | -438.56K | -42.33M |
| Financing Cash Flow | -2.43M | -2.43M | -32.08K | -68.63K | 547.61K | 11.21M |
Mach7 Technologies Technical Analysis
Mach7 Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$167.87M | 100.00 | 1.89% | ― | 10.06% | ― | |
52 Neutral | AU$19.47M | -11.32 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$55.21M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
48 Neutral | AU$102.21M | -17.05 | -12.35% | ― | 15.99% | 22.05% | |
43 Neutral | AU$78.92M | -10.35 | ― | ― | ― | ― |
Mach7 Technologies Corporate Events
Mach7 Technologies has notified the market that a total of 308,333 options (ASX code M7TAJ), which were exercisable at various prices and on various dates, have lapsed after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these options, effective on 15 October 2025 and 31 December 2025, reduces the company’s potential future dilution from option exercises and slightly simplifies its capital structure, information that may be relevant for shareholders assessing Mach7’s outstanding securities and potential equity overhang.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.44 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has confirmed that the U.S. Veterans Health Administration will halt its NextGen PACS program for the National Teleradiology Program, resulting in the termination of the multi‑vendor project in which Mach7 was a subcontractor. The decision means the VHA will retain its incumbent imaging vendor and that neither the already‑implemented Phase 1, covering limited go‑live in mammography and telestroke, nor the planned Phase 2 will proceed, despite Mach7 having met its initial contractual obligations. While management described the outcome as disappointing, they emphasised that the highly complex, bespoke government project demanded substantial resources and that its cancellation does not alter Mach7’s strategic focus on its broader commercial pipeline, where deal velocity and payment terms are more attractive, and on sustaining growth in recurring revenue and profitability.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies will release its Q2 FY26 results for the quarter ended 31 December 2025 on 30 January 2026 and will follow the announcement with an investor webinar hosted by CEO Teri Thomas and CFO Dan Lee. The session, open to the investment community and later available as a recording on the company’s investor relations site, underscores Mach7’s ongoing engagement with shareholders and market participants ahead of a key quarterly update for the medical imaging software specialist.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has notified the ASX that a total of 160,000 options over its shares have lapsed after failing to meet required vesting or performance conditions by their respective expiry dates. The cessation of these conditional rights, which relate to various option series expiring on different dates and at different exercise prices, results in a reduction of potential future dilution for existing shareholders and reflects an adjustment to the company’s issued capital structure, but does not involve any new capital raising or cash outflow.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced the cessation of 73,334 securities due to the expiry of options on November 30, 2025. This development reflects the company’s ongoing management of its financial instruments and capital structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced a change in the director’s interest, with Teri Jo Thomas acquiring 1,989,189 Performance Rights under the company’s Long Term Incentive Plan. This move, approved at the 2025 Annual General Meeting, reflects the company’s commitment to aligning its leadership’s interests with long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced the issuance of 1,989,189 unquoted performance rights under an employee incentive scheme. This move is part of the company’s strategy to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has signed a 5-year subscription license agreement with UnityPoint Health for its new Flamingo Architecture product, marking the first commercial deployment of this modular offering. This agreement is expected to contribute significantly to Mach7’s annual recurring revenue, starting at approximately A$0.6 million and potentially growing to A$1 million over five years, as usage increases. This deal highlights Mach7’s strategic shift and potential for growth in the healthcare imaging industry.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies announced the results of its Annual General Meeting, where all resolutions were passed by a poll. Key resolutions included the adoption of the Remuneration Report, the re-election of Dr. Eliot Siegel as a Director, and the issuance of Performance Rights to CEO & Managing Director Ms. Teri Thomas. These outcomes reflect strong shareholder support and are likely to positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies announced the presentation of documents at its Annual General Meeting, emphasizing its commitment to delivering innovative medical imaging software solutions. This announcement highlights the company’s strategic focus on expanding its global network and enhancing its enterprise imaging ecosystem, which could strengthen its market position and provide significant benefits to its stakeholders.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has responded to an ASX query regarding a notable increase in the trading price and volume of its securities. The company stated that it is unaware of any undisclosed information that could explain the recent trading activity and confirmed compliance with ASX Listing Rules. This response indicates that the company maintains transparency and adheres to regulatory requirements, which may reassure stakeholders about its operational integrity.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies announced that their CEO and Managing Director, Teri Thomas, will present at the Bell Potter Healthcare Conference. This presentation is expected to reinforce Mach7’s position in the healthcare technology sector by showcasing their innovative imaging solutions, potentially impacting their market presence and stakeholder engagement.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced a change in the interests of its director, Robert Bazzani, who has acquired an additional 100,000 fully paid ordinary shares through on-market purchases. This acquisition increases Bazzani’s total holding to 354,728 shares, reflecting a strategic move that may signal confidence in the company’s growth prospects and potentially impact stakeholder perceptions positively.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies reported a significant quarter with key developments including the initial deployment of its solutions in the U.S. Veterans Health Administration’s National Teleradiology Program. This quarter marked a strategic reset with leadership changes and a focus on high-value enterprise opportunities in Asia and the Middle East. The company achieved a CARR of A$29.6M and an ARR run rate of A$23.5M, highlighting its financial stability with no debt and cash reserves of A$18.9M. The company is poised for growth with a streamlined leadership team and expanded operations in Malaysia, aiming for sustained momentum and a rebound in the latter half of FY26.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has announced the successful execution of Phase 1 of its collaboration with the Veterans Health Administration’s National Teleradiology Program, providing its Vendor Neutral Archive and eUnity Diagnostic Viewer. This phase, which has a potential contract value of A$11.7 million, marks a significant milestone for Mach7, highlighting its strengths in interoperability and cloud computing. The successful rollout could lead to further expansion into the VHA hospital network, enhancing diagnostic capabilities for veterans across 125 sites.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has announced its Annual General Meeting (AGM) will be held virtually on November 28, 2025, at 10:00 am AEDT. The meeting will be conducted via a Zoom webinar, allowing shareholders to participate in real-time by listening to proceedings, viewing presentations, asking questions, and voting. The company encourages shareholders to lodge their proxies by November 26, 2025, and provides options for accessing meeting-related documents electronically or physically. This virtual AGM reflects the company’s commitment to engaging with its stakeholders while leveraging technology to facilitate participation.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This announcement reinforces Mach7’s dedication to maintaining robust governance practices, which is crucial for its stakeholders and enhances its reputation in the healthcare technology sector.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies’ Annual Report for FY25 highlights its strategic direction, product innovation, and customer impact. The report emphasizes the company’s commitment to transparency, strategic execution, and improving clinical outcomes through its enterprise imaging platform. Key priorities include enhancing clinical impact, delivering customer value, and advancing product development. The company aims to drive sustainable growth through strategic partnerships and operational excellence, reflecting its dedication to long-term value creation for stakeholders.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.